NAPSRX CNPR EXAM (REVISED
18TH EDITION) WITH ALL 100%
CORRECT ANSWERS
whatNdoesNaNSTATNorderNmean?N-NcorrectNanswer-
aNdrugNneededNimmediatelyNandNgivenNonlyNonce
whatNinformationNdoesNtheNoverdosageNsectionNofNtheNlabelingNprovide?N-
NcorrectNanswer-signs,NsymptomsNandNtreatmentNofNacuteNoverdoses
typesNofNdrug-drugNinteractions:N-NcorrectNanswer-
duplication,NoppositionN(antagonism)NandNalterationN(p.51)
toleranceNvsNresistanceN-NcorrectNanswer-
toleranceNisNtheNdiminishedNresponseNtoNaNdrug;NresistanceNisNtheNcellsNabilityNto
NresistNtheNeffectsNofNtheNdrugNonNthem.
abbreviatedNnewNdrugNapplicationN(ANDA)N-NcorrectNanswer-
theNprocessNbyNwhichNapplicantsNmustNscientificallyNdemonstrateNtoNtheNFDANthat
NtheirNgenericNproductNisNbioequivalentNtoNorNperformsNinNtheNsameNwayNasNtheNi
nnovatorNdrug,NnoNduplicateNtestingN(p.N75)
theNHatch-WaxmanNActNofN1984N-NcorrectNanswer--
A.K.A.NDrugNPriceNCompetitionNandNPatentNRestorationNAct
, -
madeNitNeasierNtoNbringNgenericNdrugsNtoNtheNmarketNbyNrequiringNtheNFDANtoNon
lyNlookNatNbioavailabilityNstudiesNinNorderNtoNapproveNanNANDA.
-gaveNprotectionNtoNtheNresearchNbasedNmanufacturersNbyNprovidingNaN30-
monthNautomaticNcoolingNoffNperiodNonceNanNANDANisNchallengedNforNpatentNinfri
ngementN(p.N75)
fourNbasicNtransportNmechanismsN-NcorrectNanswer-
passiveNdiffusion,NfacilitatedNdiffusion,NactiveNtransport,NandNpinocytosisN(p.N95)
potencyNvsNefficacyN-NcorrectNanswer-
potency:NamountNofNdrugNnecessaryNtoNproduceNdesiredNeffect
efficacy:NmagnitudeNofNmaximalNresponseNthatNcanNbeNreceivedNfromNaNdrug
*efficacyNisNalmostNalwaysNmoreNimportantNthatNpotency*N(p.N106)
theNfourNphasesNofNclinicalNtrialsN-NcorrectNanswer-phasesNI-IVN(P.N124-126)
KeyNPartsNOfNANClinicalNPaperN(5)N-NcorrectNanswer-
Abstract,NIntroduction,Nmethods,Nresults,Ndiscussion/conclusionsN(p.N128-129)
reliabilityNvsNvalidityN-NcorrectNanswer-
reliabilityN=NconsistencyNandNvalidityN=Naccuracy
(p.N138;N143)
samplingNerrorNvsNselectionNbiasN-NcorrectNanswer-
samplingNerrorNisNunbiasedNandNisNrandomlyNchosenNfromNtheNpopulation.N
selectionNbiasNisNwhenNtheNsampleNwasNspecificallyNchosenNbasedNonNparticularNc
haracteristicsN(p.142-143)
independentNvsNdependentNvariableN-NcorrectNanswer-
AnNindependentNvariableNisNtheNoneNthatNinfluencesNtheNvariation.NANdependentNv
ariableNisNtheNvariableNbeingNtestedNandNmeasuredNinNaNscientificNexperimentN(the
NresultNofNapplyingNtheNindependentNvariable).
DrugNUtilizationNReviewN(DUR)NprogramsN-NcorrectNanswer--
involveNretrospectiveNmonitoringNofNphysicians'NprescribingNpatterns
-moreNthanN90%NofNHMOsNrequireNDURs
-nowadaysNmostlyNmonitorsNcostNsavingsN(p.N181)
opportunityNcostN-NcorrectNanswer-
basedNonNtheNpremiseNthatNallNresourcesNareNscarce,NandNthereforeNeveryNtimeNw
eNchooseNtoNuseNaNresourceNitNreducesNtheNpossibilityNofNitNbeingNusedNinNanothe
rNway.
whatNtypeNofNDTCNadvertisingNisNtheNonlyNlegalNformNinNEurope?N-
NcorrectNanswer-Disease-
stateNorNunbrandedNadsN(providesNpublicNinformationNonNaNdisease,NnotNaNdrug)
(p.N223)
18TH EDITION) WITH ALL 100%
CORRECT ANSWERS
whatNdoesNaNSTATNorderNmean?N-NcorrectNanswer-
aNdrugNneededNimmediatelyNandNgivenNonlyNonce
whatNinformationNdoesNtheNoverdosageNsectionNofNtheNlabelingNprovide?N-
NcorrectNanswer-signs,NsymptomsNandNtreatmentNofNacuteNoverdoses
typesNofNdrug-drugNinteractions:N-NcorrectNanswer-
duplication,NoppositionN(antagonism)NandNalterationN(p.51)
toleranceNvsNresistanceN-NcorrectNanswer-
toleranceNisNtheNdiminishedNresponseNtoNaNdrug;NresistanceNisNtheNcellsNabilityNto
NresistNtheNeffectsNofNtheNdrugNonNthem.
abbreviatedNnewNdrugNapplicationN(ANDA)N-NcorrectNanswer-
theNprocessNbyNwhichNapplicantsNmustNscientificallyNdemonstrateNtoNtheNFDANthat
NtheirNgenericNproductNisNbioequivalentNtoNorNperformsNinNtheNsameNwayNasNtheNi
nnovatorNdrug,NnoNduplicateNtestingN(p.N75)
theNHatch-WaxmanNActNofN1984N-NcorrectNanswer--
A.K.A.NDrugNPriceNCompetitionNandNPatentNRestorationNAct
, -
madeNitNeasierNtoNbringNgenericNdrugsNtoNtheNmarketNbyNrequiringNtheNFDANtoNon
lyNlookNatNbioavailabilityNstudiesNinNorderNtoNapproveNanNANDA.
-gaveNprotectionNtoNtheNresearchNbasedNmanufacturersNbyNprovidingNaN30-
monthNautomaticNcoolingNoffNperiodNonceNanNANDANisNchallengedNforNpatentNinfri
ngementN(p.N75)
fourNbasicNtransportNmechanismsN-NcorrectNanswer-
passiveNdiffusion,NfacilitatedNdiffusion,NactiveNtransport,NandNpinocytosisN(p.N95)
potencyNvsNefficacyN-NcorrectNanswer-
potency:NamountNofNdrugNnecessaryNtoNproduceNdesiredNeffect
efficacy:NmagnitudeNofNmaximalNresponseNthatNcanNbeNreceivedNfromNaNdrug
*efficacyNisNalmostNalwaysNmoreNimportantNthatNpotency*N(p.N106)
theNfourNphasesNofNclinicalNtrialsN-NcorrectNanswer-phasesNI-IVN(P.N124-126)
KeyNPartsNOfNANClinicalNPaperN(5)N-NcorrectNanswer-
Abstract,NIntroduction,Nmethods,Nresults,Ndiscussion/conclusionsN(p.N128-129)
reliabilityNvsNvalidityN-NcorrectNanswer-
reliabilityN=NconsistencyNandNvalidityN=Naccuracy
(p.N138;N143)
samplingNerrorNvsNselectionNbiasN-NcorrectNanswer-
samplingNerrorNisNunbiasedNandNisNrandomlyNchosenNfromNtheNpopulation.N
selectionNbiasNisNwhenNtheNsampleNwasNspecificallyNchosenNbasedNonNparticularNc
haracteristicsN(p.142-143)
independentNvsNdependentNvariableN-NcorrectNanswer-
AnNindependentNvariableNisNtheNoneNthatNinfluencesNtheNvariation.NANdependentNv
ariableNisNtheNvariableNbeingNtestedNandNmeasuredNinNaNscientificNexperimentN(the
NresultNofNapplyingNtheNindependentNvariable).
DrugNUtilizationNReviewN(DUR)NprogramsN-NcorrectNanswer--
involveNretrospectiveNmonitoringNofNphysicians'NprescribingNpatterns
-moreNthanN90%NofNHMOsNrequireNDURs
-nowadaysNmostlyNmonitorsNcostNsavingsN(p.N181)
opportunityNcostN-NcorrectNanswer-
basedNonNtheNpremiseNthatNallNresourcesNareNscarce,NandNthereforeNeveryNtimeNw
eNchooseNtoNuseNaNresourceNitNreducesNtheNpossibilityNofNitNbeingNusedNinNanothe
rNway.
whatNtypeNofNDTCNadvertisingNisNtheNonlyNlegalNformNinNEurope?N-
NcorrectNanswer-Disease-
stateNorNunbrandedNadsN(providesNpublicNinformationNonNaNdisease,NnotNaNdrug)
(p.N223)